

Operational Update

Responding to Mpox, resources and process updates

Date published: 19 September 2024

- Updates on Mpox
- Process updates: Implementation oversight
- Request for proposals
- Resources: Information Sessions and Documents

Dear colleagues,

In this Operational Update, we would like to share information on the Global Fund's efforts to support country partners during emergency responses by reinvesting existing grant funding. Repurposing existing funding allows countries to be able to respond faster and in an agile manner.

Following the public health emergency <u>declarations</u> by Africa CDC and WHO on mpox, countries with HIV grants and C19RM funding can repurpose funds to support eligible interventions to contain the spread of the virus. The Global Fund issued a technical brief to respond to mpox in 2022 and it has now been updated. Activities that can be supported include systems strengthening of core prevention, early detection and response functions, such as disease surveillance, laboratory capacity, community engagement and surge workforce. More information on the technical brief can be found below.

In addition, this update brings you information on a multicountry request for proposals, a series of information sessions for country partners on mpox, risk management, and an updated list of documents and guidance to support implementation of Global Fund grants, including on reporting process (implementation oversight).

We would like to thank you for your continued engagement in fighting the three diseases and strengthening systems for health.

Best regards,

For questions please contact operational.communications@theglobalfund.org.

1. Updates on Mpox

Technical brief and information session. The Global Fund's technical brief to Prevent,
Detect and Respond to Mpox now includes an updated Annex 1 with interventions supported
by the Global Fund and a new Annex 2 with eligible diagnostics for mpox available on
wambo.org. Existing C19RM funds and HIV allocation funding can be reinvested to respond to
countries' needs. An information session for country partners is upcoming. Invitations will be
shared soon. Technical brief: English | Français | Português

2. Process updates: Implementation oversight

- LFA review of the mid-term PU and FCR. PRs are requested not to share forms with the LFA for review. This will happen automatically once the PR submits the online form through the Partner Portal. LFAs will receive detailed guidance directly from the Global Fund. For technical issues, please contact country.support@theglobalfund.org for support in English, French and Spanish.
- **Reminder.** For PUDR and Final PUs with reporting end date of 30 June, PRs are reminded to use the old forms (online forms are not applicable).
- The new interactive PR Reporting Handbook for GC7 replaces the Pulse Check Instructions, PU/DR Guidelines and the Partner Portal Guides and provides guidance to PRs on Global Fund reporting. (English | Español | Français)
- Partner Portal demos. Short videos on PR Reporting guide PRs through each step of the process to complete and submit online forms.
 - o Pulse Checks: English | Français
 - o PU/DR: English | Français
 - o FCR: English
- Information sessions. The enhanced final PU and PUDR reports are expected to become available in the Partner Portal at the end of 2024/early 2025. Information sessions for PRs and LFAs will be organized in English, French and Spanish to introduce the changes with invitations coming in November.

3. Request for proposals

The Global Fund has launched a call for proposals from regional stakeholders in Middle
East and North Africa, West and Central Africa, and Latin America and the Caribbean to
implement multicountry grants on HIV incidence reduction. More information about proposal
templates, application instructions and deadlines for each region is available on the Global
Fund website.

4. Resources: Information sessions and documents

Information sessions

- Global Fund support to mpox response. Organized with WHO and Africa CDC this
 information session will cover the joint mpox preparedness and response plan as well as the
 possibility to reinvest Global Fund funding from HIV grants and C19RM. The session will be
 held in English with simultaneous interpretation into French and Portuguese. The invitation will
 be sent separately.
- Global Fund Risk Management. This session will focus on key concepts of risk management, the Global Fund's approach to country Risk Management, the Risk Management Life Cycle and the roles of PRs, CCMs and LFAs in effective risk management. An invitation will be sent separately.

Documents

Updated COVID-19 Response Mechanism Guidelines

The COVID-19 Response Mechanism (C19RM) Guidelines have been updated with instructions on how to close the C19RM component of GC6 grants (English | Español | Français). These updates are in line with the standard closure process detailed in the OPN and Operational Procedures on IP Reconciliation and Grant Closures, with some C19RM-specific considerations.

• Strengthening Gender Approaches in Malaria Response

This document provides insights on integrating gender-responsive and gender-transformative considerations into malaria programs (<u>English</u>), for stakeholders who are designing, implementing, and evaluating malaria programs in-country. Translations into French and Portuguese are forthcoming and will be available on the <u>Global Fund website</u>.

• The Global Fund's Requirements for Victim/Survivor Support Services. The victim/survivor support services protocol outlines the Global Fund's requirements in response

to allegations of sexual exploitation, abuse and harassment (<u>English</u> | <u>Français</u>). Translations into Spanish and Portuguese are forthcoming.

New HIV Product Resources

- Navigating Market Changes to Sustain CD4 summarizes the latest CD4 market dynamics, including manufacturer discontinuations, that should be addressed by national HIV programs in procurement and implementation decision-making (<u>English</u> | <u>Español</u> | <u>Français</u>).
- Managing Tenofovir Demand clarifies the Global Fund's support to TAF formulations for HIV treatment and highlights the key clinical, market, and programmatic considerations PRs need to assess before considering product adoption and procurement (<u>English</u> | <u>Español</u> | <u>Français</u>).
- New Oral Pre-exposure Prophylaxis summarizes the cost and supply security benefits of using tenofovir disoproxil fumarate + lamivudine (TDF/3TC) for oral PrEP (English).
- Antiretroviral Drugs for HIV Treatment, Infant Prophylaxis, and Prevention includes clinical indication and intended use, quantification pointers, and market considerations for the >40 ARVs routinely procured by Principal Recipients for HIV treatment, infant prophylaxis and prevention (English | Español | Français).

• The Global Fund's Funding for Community and Civil Society Organizations

The <u>report</u> provides an analysis of the Global Fund's investments in communities and civil society organizations and their role in shaping responses to three diseases from 2017-2022.

Progress to Reduce Human Rights-related Barriers to HIV, TB and Malaria Services

The <u>report</u> summarizes the impact of the Global Fund's global Breaking Down Barriers initiative to support 20 countries in scaling up programs and interventions to remove human rights-related obstacles in accessing HIV, TB and malaria services.